2025 Q4 -tulosraportti
Vain PDF
55 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 533 | - | - | ||
| 650 | - | - | ||
| 100 | - | - | ||
| 1 470 | - | - | ||
| 155 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten · MuokattuBecause blueoceanguy very aggressively attacks Stenocare and has made claims that Stenocare as a company has no business in Germany, and that they will not make money in Germany, I set out to find articles, or something similar, that would show that Stenocare as a company will indeed make a lot of money in the German market. It has not been a straightforward path; it was very complicated. I found that the German system is completely different from the Danish one, and that the way the German system is structured will actually be an advantage for Stenocare's earnings. What I have found out, I share below, which you can read if it interests you. For clarity, I have put it in bullet points. 1. Astrum 10-10 is approved for 100% reimbursement by two insurance companies (Techniker Krankenkasse and AOK Rheinland, which together have about 14 million members) where the medicine will be free, but in Germany, one apparently pays a prescription fee, from 30-75kr. per prescription. As long as there is 100% reimbursement, and a person has started using Astrum 10-10, and it works as it should, it will be rare for people to switch to another brand. This will provide continuous sales of Astrum 10-10 2. In Germany, public reimbursement is called reimbursement, and this reimbursement will be the primary reason why Astrum 10-10 will become very valuable for Stenocare's earnings. 3. Doctors in Germany are more inclined to prescribe medicine with the highest subsidy than medicine with less than 100% subsidy, because doctors want to ensure that their patients can afford to buy the medicine. 4. But in Germany, doctors have a fixed budget for each quarter for medicine they prescribe to their patients, and which they must adhere to. If doctors only prescribe the most expensive medicine, that is, only medicine that insurance companies have not approved for reimbursement, which would cause doctors to exceed the fixed budget, then the doctors themselves will have to pay the difference out of their own pocket to the public. Astrum 10-10 is approved for 100% reimbursement, so prescribing Astrum 10-10 to their patients will not affect the doctors' budget. This also means that Astrum 10-10 is not price-sensitive in Germany, compared to a product that is not approved for 100% reimbursement. 5. German doctors also consider whether the medicine they prescribe has a positive effect on their patients, and whether the medicine's content complies with what is stated on the label, but also look at whether there is reimbursement, for the reasons mentioned above. 6. In Germany, doctors must write an application for their patients the first time they want to prescribe medicine that is reimbursed. This can be complicated, so Weeco is busy teaching doctors how to correctly write the application. This process also means that doctors will not be keen for their patients to switch to another brand. This is a significant reason why Astrum 10-10 will have a stable income in Germany once the market is saturated. 7. Finally, Germany is considered a growth market, see link below Explanation of telemedical service. At the time of writing, one must appear in person for the first prescription, subsequently within 12 mths., one can call the doctor and get a prescription, and it is forbidden to send flower medicine by post, but pharmacies are allowed to send cannabis oil by post. This point is not yet clarified in Germany. When Stenocare claims that Astrum 10-10 will become very valuable for Stenocare's earnings, I believe that is absolutely correct. Germany is considered a growth market for prescription medical cannabis https://businessofcannabis.com/new-report-uk-and-germany-medical-cannabis-markets-both-double-in-2025/·13 t sittenOk You are talking about what happened in the past and I am talking about 2025 and what I expect in 2026 etc. I have been in the archives to find out what actually happened with sales in Germany from August 2023. Stenocare started selling Medical cannabis in August 2023 in Germany, without any form of reimbursement. Sales were slower than expected. In 2023 Stenocare got a partner ADREXpharma In January 2025, Astrum 10-10 was approved as a prescription medicine in Germany. Still no reimbursement. In April 2025, Astrum 10-10 was approved for 100% reimbursement. Efforts were made to roll out Astrum 10-10 in Germany, and their partner ADREXpharma educates doctors on how to write an application for their patients. The annual report for 2025, as you write, was primarily driven by the Danish market. In January 2026, it was announced that Weeco would be the No. 2 partner in Germany.. In February 2026, Weeco and ADREXpharma began collaborating to roll out Astrum 10-10 (ADREXpharma and WEECO are connected to the central wholesale systems, therefore they can deliver to all pharmacies in Germany, approx. 18,000 pharmacies. What Weeco and ADREXpharma are currently doing is getting in touch with all the doctors in their network, partly to promote Astrum 10-10 and partly to educate them on how to write an application for their patients. Weeco has over 5,000 general practitioners and specialists. in their network who prescribe medical cannabis, and ADREXpharma has approx. 2,000–3,000 specialists, primarily in pain, oncology, and neurology, who already regularly prescribe medical cannabis. With these two heavyweights as Stenocare's partners, and Astrum 10-10 being approved for 100% reimbursement, my expectations for the German market are that Stenocare will achieve significant revenues from there, as doctors begin to prescribe Astrum10-10. Due to trade secrecy, it is not possible for a private person to find out, via statistics or other devious ways, how many prescriptions for Astrum 10-10 have been issued in Germany until now. So we must wait until Stenocare itself announces how things have gone in Germany in 2026.
·5 t sittenYou can access the sales of medical cannabis in Denmark via public channels (of course, a bit retrospective - the Danish Health Data Authority publishes with a delay). When you take this figure and compare it to the total revenue STENOCARE itself reports, and subtract the Danish portion, the remaining amount is MINIMAL - read: less than 10 % - and it is precisely this portion that must cover the sales for all foreign markets combined (Germany, Norway, etc.). Based on this, I clearly emphasize that your writings and statements are hot air and wishful thinking - not reality. And it will not be the reality in the next financial report either, as this is driven by something completely different (read: the acquisition of CannGros). I have previously commented on what our expectations for Q1-2026 specifically are - see excerpt below: "Our expectation Base-scenario: STENOCARE Group's Danish revenue in Q1-2026 lands in the range of DKK 4.0-4.5 million - corresponding to a doubling vs. Q1-2025 (ex. CannGros) and a significant uplift vs. the mere sum of STENOCARE+CannGros' 2025-quarterly average (approx. 3.9 million). Bull-scenario: If Bedrocan recovery proves faster than expected, and CBD100/THC-CBD 1:1 continues its adoption curve, Q1 could land in the range of DKK 4.8-5.2 million. Bear-scenario: Continued Scanleaf pressure and slower CannGros integration could pull Q1 down towards DKK 3.5-3.8 million - still decent growth, but below the full potential line. What we are particularly looking for Three signals will be crucial to assess whether STENOCARE is on the right track: Firstly, the development in CannGros' Bedrocan share vs. Scanleaf's - here, the Q1 figures are the first real temperature measurement after CannGros has come under the STENOCARE umbrella. Secondly, whether CBD100 and THC/CBD 1:1 continue their adoption curve or show signs of plateauing. Thirdly, whether the 14-day price discipline holds on medicinpriser.dk - or if someone breaks out and starts price competition. Until the Q1 figures from the Danish Health Data Authority are published, these are the best indications we have - and they suggest that STENOCARE domestically is in a significantly stronger position at the beginning of 2026 than they were at the beginning of 2025."- ·17.4.I am starting a new thread. I wrote a post as a continuation of another one a little while ago, But it got lost. Astrum 10-10 is being sold through Weecos' network in Germany. Sales started on February 1, 2026. Therefore, we cannot yet see the sales from there in the financial statements. Stenocare sells through its partner Weeco, who uses its network. The doctors are still in the training period, which is an advantage for Stenocare, because their product Astrum 10-10 is included in the first wave. My expectations for the doctors in Germany are that they will welcome Astrum 10-10, because the medicine meets all the requirements that doctors have continuously made for medical cannabis, if they are to prescribe prescriptions; these requirements continuously emerged in various articles before Germany released medical cannabis. I have listed these requirements in bullet points, and Stenocare can tick off all the requirements, because Astrum 10-10 meets them all 1. The medicine must have the strength stated on the label in all batches. 2. It must work within the time the manufacturer promises 3. It must meet the strict requirements that Germany demands 4. It must be approved by their insurance companies 5. That there is reimbursement for the medicine 6. That doctors can count on a consistent absorption every time. Therefore, my expectations are that Astrum 10-10 will perform well in Germany, as doctors are trained in the product.·17.4.Germany is irrelevant for StenoCare.
- ·16.4.The USA is further ahead than Europe regarding research into medical cannabis, etc. Therefore, I also find articles about research over there. Researchers have found out. that CBD is better to use as sleep medicine, because people fall asleep and dream. It is commonly known that traditional sleep medicine deprives people of their dreams, which causes some bad side effects. Sleep problems are also a phenomenon outside the USA, personally I know several, and who use CBD oil to fall asleep, they have the same good experience. https://www.nugmag.com/cbd-for-better-sleep-discovering-its-powerful-effects/
·9.4.Much resistance so far.·16.4.Rolf, most of my money is placed in good solid companies that have proven their worth over time. Then I have a small sum of money that I play around with a bit, and occasionally take higher risks with, for example, in smaller companies. I have a small portion of stenocare. I honestly don't know how much I believe in them. They probably have a chance, but can also end up like so many other First North companies, meaning going down. When I buy these risk stocks, I often have a two-pronged strategy. Partly the typical one, where a purchase will yield a profit if it truly goes well. And then the alternative , where my purchase isn't really a bet on the company itself, but where I, so to speak, more bet on scoring a profit from there seeming to be a fixed group of perma-optimists who always seem ready to egg each other on to buy big and thereby trigger large increases, even when there's no reason. And when that happens, I don't hesitate to sell…and then I just wait for it to fall down again
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
55 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuBecause blueoceanguy very aggressively attacks Stenocare and has made claims that Stenocare as a company has no business in Germany, and that they will not make money in Germany, I set out to find articles, or something similar, that would show that Stenocare as a company will indeed make a lot of money in the German market. It has not been a straightforward path; it was very complicated. I found that the German system is completely different from the Danish one, and that the way the German system is structured will actually be an advantage for Stenocare's earnings. What I have found out, I share below, which you can read if it interests you. For clarity, I have put it in bullet points. 1. Astrum 10-10 is approved for 100% reimbursement by two insurance companies (Techniker Krankenkasse and AOK Rheinland, which together have about 14 million members) where the medicine will be free, but in Germany, one apparently pays a prescription fee, from 30-75kr. per prescription. As long as there is 100% reimbursement, and a person has started using Astrum 10-10, and it works as it should, it will be rare for people to switch to another brand. This will provide continuous sales of Astrum 10-10 2. In Germany, public reimbursement is called reimbursement, and this reimbursement will be the primary reason why Astrum 10-10 will become very valuable for Stenocare's earnings. 3. Doctors in Germany are more inclined to prescribe medicine with the highest subsidy than medicine with less than 100% subsidy, because doctors want to ensure that their patients can afford to buy the medicine. 4. But in Germany, doctors have a fixed budget for each quarter for medicine they prescribe to their patients, and which they must adhere to. If doctors only prescribe the most expensive medicine, that is, only medicine that insurance companies have not approved for reimbursement, which would cause doctors to exceed the fixed budget, then the doctors themselves will have to pay the difference out of their own pocket to the public. Astrum 10-10 is approved for 100% reimbursement, so prescribing Astrum 10-10 to their patients will not affect the doctors' budget. This also means that Astrum 10-10 is not price-sensitive in Germany, compared to a product that is not approved for 100% reimbursement. 5. German doctors also consider whether the medicine they prescribe has a positive effect on their patients, and whether the medicine's content complies with what is stated on the label, but also look at whether there is reimbursement, for the reasons mentioned above. 6. In Germany, doctors must write an application for their patients the first time they want to prescribe medicine that is reimbursed. This can be complicated, so Weeco is busy teaching doctors how to correctly write the application. This process also means that doctors will not be keen for their patients to switch to another brand. This is a significant reason why Astrum 10-10 will have a stable income in Germany once the market is saturated. 7. Finally, Germany is considered a growth market, see link below Explanation of telemedical service. At the time of writing, one must appear in person for the first prescription, subsequently within 12 mths., one can call the doctor and get a prescription, and it is forbidden to send flower medicine by post, but pharmacies are allowed to send cannabis oil by post. This point is not yet clarified in Germany. When Stenocare claims that Astrum 10-10 will become very valuable for Stenocare's earnings, I believe that is absolutely correct. Germany is considered a growth market for prescription medical cannabis https://businessofcannabis.com/new-report-uk-and-germany-medical-cannabis-markets-both-double-in-2025/·13 t sittenOk You are talking about what happened in the past and I am talking about 2025 and what I expect in 2026 etc. I have been in the archives to find out what actually happened with sales in Germany from August 2023. Stenocare started selling Medical cannabis in August 2023 in Germany, without any form of reimbursement. Sales were slower than expected. In 2023 Stenocare got a partner ADREXpharma In January 2025, Astrum 10-10 was approved as a prescription medicine in Germany. Still no reimbursement. In April 2025, Astrum 10-10 was approved for 100% reimbursement. Efforts were made to roll out Astrum 10-10 in Germany, and their partner ADREXpharma educates doctors on how to write an application for their patients. The annual report for 2025, as you write, was primarily driven by the Danish market. In January 2026, it was announced that Weeco would be the No. 2 partner in Germany.. In February 2026, Weeco and ADREXpharma began collaborating to roll out Astrum 10-10 (ADREXpharma and WEECO are connected to the central wholesale systems, therefore they can deliver to all pharmacies in Germany, approx. 18,000 pharmacies. What Weeco and ADREXpharma are currently doing is getting in touch with all the doctors in their network, partly to promote Astrum 10-10 and partly to educate them on how to write an application for their patients. Weeco has over 5,000 general practitioners and specialists. in their network who prescribe medical cannabis, and ADREXpharma has approx. 2,000–3,000 specialists, primarily in pain, oncology, and neurology, who already regularly prescribe medical cannabis. With these two heavyweights as Stenocare's partners, and Astrum 10-10 being approved for 100% reimbursement, my expectations for the German market are that Stenocare will achieve significant revenues from there, as doctors begin to prescribe Astrum10-10. Due to trade secrecy, it is not possible for a private person to find out, via statistics or other devious ways, how many prescriptions for Astrum 10-10 have been issued in Germany until now. So we must wait until Stenocare itself announces how things have gone in Germany in 2026.·5 t sittenYou can access the sales of medical cannabis in Denmark via public channels (of course, a bit retrospective - the Danish Health Data Authority publishes with a delay). When you take this figure and compare it to the total revenue STENOCARE itself reports, and subtract the Danish portion, the remaining amount is MINIMAL - read: less than 10 % - and it is precisely this portion that must cover the sales for all foreign markets combined (Germany, Norway, etc.). Based on this, I clearly emphasize that your writings and statements are hot air and wishful thinking - not reality. And it will not be the reality in the next financial report either, as this is driven by something completely different (read: the acquisition of CannGros). I have previously commented on what our expectations for Q1-2026 specifically are - see excerpt below: "Our expectation Base-scenario: STENOCARE Group's Danish revenue in Q1-2026 lands in the range of DKK 4.0-4.5 million - corresponding to a doubling vs. Q1-2025 (ex. CannGros) and a significant uplift vs. the mere sum of STENOCARE+CannGros' 2025-quarterly average (approx. 3.9 million). Bull-scenario: If Bedrocan recovery proves faster than expected, and CBD100/THC-CBD 1:1 continues its adoption curve, Q1 could land in the range of DKK 4.8-5.2 million. Bear-scenario: Continued Scanleaf pressure and slower CannGros integration could pull Q1 down towards DKK 3.5-3.8 million - still decent growth, but below the full potential line. What we are particularly looking for Three signals will be crucial to assess whether STENOCARE is on the right track: Firstly, the development in CannGros' Bedrocan share vs. Scanleaf's - here, the Q1 figures are the first real temperature measurement after CannGros has come under the STENOCARE umbrella. Secondly, whether CBD100 and THC/CBD 1:1 continue their adoption curve or show signs of plateauing. Thirdly, whether the 14-day price discipline holds on medicinpriser.dk - or if someone breaks out and starts price competition. Until the Q1 figures from the Danish Health Data Authority are published, these are the best indications we have - and they suggest that STENOCARE domestically is in a significantly stronger position at the beginning of 2026 than they were at the beginning of 2025."
- ·17.4.I am starting a new thread. I wrote a post as a continuation of another one a little while ago, But it got lost. Astrum 10-10 is being sold through Weecos' network in Germany. Sales started on February 1, 2026. Therefore, we cannot yet see the sales from there in the financial statements. Stenocare sells through its partner Weeco, who uses its network. The doctors are still in the training period, which is an advantage for Stenocare, because their product Astrum 10-10 is included in the first wave. My expectations for the doctors in Germany are that they will welcome Astrum 10-10, because the medicine meets all the requirements that doctors have continuously made for medical cannabis, if they are to prescribe prescriptions; these requirements continuously emerged in various articles before Germany released medical cannabis. I have listed these requirements in bullet points, and Stenocare can tick off all the requirements, because Astrum 10-10 meets them all 1. The medicine must have the strength stated on the label in all batches. 2. It must work within the time the manufacturer promises 3. It must meet the strict requirements that Germany demands 4. It must be approved by their insurance companies 5. That there is reimbursement for the medicine 6. That doctors can count on a consistent absorption every time. Therefore, my expectations are that Astrum 10-10 will perform well in Germany, as doctors are trained in the product.·17.4.Germany is irrelevant for StenoCare.
- ·16.4.The USA is further ahead than Europe regarding research into medical cannabis, etc. Therefore, I also find articles about research over there. Researchers have found out. that CBD is better to use as sleep medicine, because people fall asleep and dream. It is commonly known that traditional sleep medicine deprives people of their dreams, which causes some bad side effects. Sleep problems are also a phenomenon outside the USA, personally I know several, and who use CBD oil to fall asleep, they have the same good experience. https://www.nugmag.com/cbd-for-better-sleep-discovering-its-powerful-effects/
- ·9.4.Much resistance so far.·16.4.Rolf, most of my money is placed in good solid companies that have proven their worth over time. Then I have a small sum of money that I play around with a bit, and occasionally take higher risks with, for example, in smaller companies. I have a small portion of stenocare. I honestly don't know how much I believe in them. They probably have a chance, but can also end up like so many other First North companies, meaning going down. When I buy these risk stocks, I often have a two-pronged strategy. Partly the typical one, where a purchase will yield a profit if it truly goes well. And then the alternative , where my purchase isn't really a bet on the company itself, but where I, so to speak, more bet on scoring a profit from there seeming to be a fixed group of perma-optimists who always seem ready to egg each other on to buy big and thereby trigger large increases, even when there's no reason. And when that happens, I don't hesitate to sell…and then I just wait for it to fall down again
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 533 | - | - | ||
| 650 | - | - | ||
| 100 | - | - | ||
| 1 470 | - | - | ||
| 155 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
55 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten · MuokattuBecause blueoceanguy very aggressively attacks Stenocare and has made claims that Stenocare as a company has no business in Germany, and that they will not make money in Germany, I set out to find articles, or something similar, that would show that Stenocare as a company will indeed make a lot of money in the German market. It has not been a straightforward path; it was very complicated. I found that the German system is completely different from the Danish one, and that the way the German system is structured will actually be an advantage for Stenocare's earnings. What I have found out, I share below, which you can read if it interests you. For clarity, I have put it in bullet points. 1. Astrum 10-10 is approved for 100% reimbursement by two insurance companies (Techniker Krankenkasse and AOK Rheinland, which together have about 14 million members) where the medicine will be free, but in Germany, one apparently pays a prescription fee, from 30-75kr. per prescription. As long as there is 100% reimbursement, and a person has started using Astrum 10-10, and it works as it should, it will be rare for people to switch to another brand. This will provide continuous sales of Astrum 10-10 2. In Germany, public reimbursement is called reimbursement, and this reimbursement will be the primary reason why Astrum 10-10 will become very valuable for Stenocare's earnings. 3. Doctors in Germany are more inclined to prescribe medicine with the highest subsidy than medicine with less than 100% subsidy, because doctors want to ensure that their patients can afford to buy the medicine. 4. But in Germany, doctors have a fixed budget for each quarter for medicine they prescribe to their patients, and which they must adhere to. If doctors only prescribe the most expensive medicine, that is, only medicine that insurance companies have not approved for reimbursement, which would cause doctors to exceed the fixed budget, then the doctors themselves will have to pay the difference out of their own pocket to the public. Astrum 10-10 is approved for 100% reimbursement, so prescribing Astrum 10-10 to their patients will not affect the doctors' budget. This also means that Astrum 10-10 is not price-sensitive in Germany, compared to a product that is not approved for 100% reimbursement. 5. German doctors also consider whether the medicine they prescribe has a positive effect on their patients, and whether the medicine's content complies with what is stated on the label, but also look at whether there is reimbursement, for the reasons mentioned above. 6. In Germany, doctors must write an application for their patients the first time they want to prescribe medicine that is reimbursed. This can be complicated, so Weeco is busy teaching doctors how to correctly write the application. This process also means that doctors will not be keen for their patients to switch to another brand. This is a significant reason why Astrum 10-10 will have a stable income in Germany once the market is saturated. 7. Finally, Germany is considered a growth market, see link below Explanation of telemedical service. At the time of writing, one must appear in person for the first prescription, subsequently within 12 mths., one can call the doctor and get a prescription, and it is forbidden to send flower medicine by post, but pharmacies are allowed to send cannabis oil by post. This point is not yet clarified in Germany. When Stenocare claims that Astrum 10-10 will become very valuable for Stenocare's earnings, I believe that is absolutely correct. Germany is considered a growth market for prescription medical cannabis https://businessofcannabis.com/new-report-uk-and-germany-medical-cannabis-markets-both-double-in-2025/·13 t sittenOk You are talking about what happened in the past and I am talking about 2025 and what I expect in 2026 etc. I have been in the archives to find out what actually happened with sales in Germany from August 2023. Stenocare started selling Medical cannabis in August 2023 in Germany, without any form of reimbursement. Sales were slower than expected. In 2023 Stenocare got a partner ADREXpharma In January 2025, Astrum 10-10 was approved as a prescription medicine in Germany. Still no reimbursement. In April 2025, Astrum 10-10 was approved for 100% reimbursement. Efforts were made to roll out Astrum 10-10 in Germany, and their partner ADREXpharma educates doctors on how to write an application for their patients. The annual report for 2025, as you write, was primarily driven by the Danish market. In January 2026, it was announced that Weeco would be the No. 2 partner in Germany.. In February 2026, Weeco and ADREXpharma began collaborating to roll out Astrum 10-10 (ADREXpharma and WEECO are connected to the central wholesale systems, therefore they can deliver to all pharmacies in Germany, approx. 18,000 pharmacies. What Weeco and ADREXpharma are currently doing is getting in touch with all the doctors in their network, partly to promote Astrum 10-10 and partly to educate them on how to write an application for their patients. Weeco has over 5,000 general practitioners and specialists. in their network who prescribe medical cannabis, and ADREXpharma has approx. 2,000–3,000 specialists, primarily in pain, oncology, and neurology, who already regularly prescribe medical cannabis. With these two heavyweights as Stenocare's partners, and Astrum 10-10 being approved for 100% reimbursement, my expectations for the German market are that Stenocare will achieve significant revenues from there, as doctors begin to prescribe Astrum10-10. Due to trade secrecy, it is not possible for a private person to find out, via statistics or other devious ways, how many prescriptions for Astrum 10-10 have been issued in Germany until now. So we must wait until Stenocare itself announces how things have gone in Germany in 2026.·5 t sittenYou can access the sales of medical cannabis in Denmark via public channels (of course, a bit retrospective - the Danish Health Data Authority publishes with a delay). When you take this figure and compare it to the total revenue STENOCARE itself reports, and subtract the Danish portion, the remaining amount is MINIMAL - read: less than 10 % - and it is precisely this portion that must cover the sales for all foreign markets combined (Germany, Norway, etc.). Based on this, I clearly emphasize that your writings and statements are hot air and wishful thinking - not reality. And it will not be the reality in the next financial report either, as this is driven by something completely different (read: the acquisition of CannGros). I have previously commented on what our expectations for Q1-2026 specifically are - see excerpt below: "Our expectation Base-scenario: STENOCARE Group's Danish revenue in Q1-2026 lands in the range of DKK 4.0-4.5 million - corresponding to a doubling vs. Q1-2025 (ex. CannGros) and a significant uplift vs. the mere sum of STENOCARE+CannGros' 2025-quarterly average (approx. 3.9 million). Bull-scenario: If Bedrocan recovery proves faster than expected, and CBD100/THC-CBD 1:1 continues its adoption curve, Q1 could land in the range of DKK 4.8-5.2 million. Bear-scenario: Continued Scanleaf pressure and slower CannGros integration could pull Q1 down towards DKK 3.5-3.8 million - still decent growth, but below the full potential line. What we are particularly looking for Three signals will be crucial to assess whether STENOCARE is on the right track: Firstly, the development in CannGros' Bedrocan share vs. Scanleaf's - here, the Q1 figures are the first real temperature measurement after CannGros has come under the STENOCARE umbrella. Secondly, whether CBD100 and THC/CBD 1:1 continue their adoption curve or show signs of plateauing. Thirdly, whether the 14-day price discipline holds on medicinpriser.dk - or if someone breaks out and starts price competition. Until the Q1 figures from the Danish Health Data Authority are published, these are the best indications we have - and they suggest that STENOCARE domestically is in a significantly stronger position at the beginning of 2026 than they were at the beginning of 2025."
- ·17.4.I am starting a new thread. I wrote a post as a continuation of another one a little while ago, But it got lost. Astrum 10-10 is being sold through Weecos' network in Germany. Sales started on February 1, 2026. Therefore, we cannot yet see the sales from there in the financial statements. Stenocare sells through its partner Weeco, who uses its network. The doctors are still in the training period, which is an advantage for Stenocare, because their product Astrum 10-10 is included in the first wave. My expectations for the doctors in Germany are that they will welcome Astrum 10-10, because the medicine meets all the requirements that doctors have continuously made for medical cannabis, if they are to prescribe prescriptions; these requirements continuously emerged in various articles before Germany released medical cannabis. I have listed these requirements in bullet points, and Stenocare can tick off all the requirements, because Astrum 10-10 meets them all 1. The medicine must have the strength stated on the label in all batches. 2. It must work within the time the manufacturer promises 3. It must meet the strict requirements that Germany demands 4. It must be approved by their insurance companies 5. That there is reimbursement for the medicine 6. That doctors can count on a consistent absorption every time. Therefore, my expectations are that Astrum 10-10 will perform well in Germany, as doctors are trained in the product.·17.4.Germany is irrelevant for StenoCare.
- ·16.4.The USA is further ahead than Europe regarding research into medical cannabis, etc. Therefore, I also find articles about research over there. Researchers have found out. that CBD is better to use as sleep medicine, because people fall asleep and dream. It is commonly known that traditional sleep medicine deprives people of their dreams, which causes some bad side effects. Sleep problems are also a phenomenon outside the USA, personally I know several, and who use CBD oil to fall asleep, they have the same good experience. https://www.nugmag.com/cbd-for-better-sleep-discovering-its-powerful-effects/
- ·9.4.Much resistance so far.·16.4.Rolf, most of my money is placed in good solid companies that have proven their worth over time. Then I have a small sum of money that I play around with a bit, and occasionally take higher risks with, for example, in smaller companies. I have a small portion of stenocare. I honestly don't know how much I believe in them. They probably have a chance, but can also end up like so many other First North companies, meaning going down. When I buy these risk stocks, I often have a two-pronged strategy. Partly the typical one, where a purchase will yield a profit if it truly goes well. And then the alternative , where my purchase isn't really a bet on the company itself, but where I, so to speak, more bet on scoring a profit from there seeming to be a fixed group of perma-optimists who always seem ready to egg each other on to buy big and thereby trigger large increases, even when there's no reason. And when that happens, I don't hesitate to sell…and then I just wait for it to fall down again
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 533 | - | - | ||
| 650 | - | - | ||
| 100 | - | - | ||
| 1 470 | - | - | ||
| 155 | - | - |
Välittäjätilasto
Dataa ei löytynyt